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Andrew McMichael
Andrew J McMichaelAndrew J McMichaelAndrew McMichael qualified in Medicine before doing
a PhD in Immunology with Ita Askonas and Alan
Williamson in the 1970s. His research during this time
and later work done in his group has made a major contri-
bution to our understanding of T-cell-mediated immunity
against viral infections. Initially he worked on the immune
response to influenza, but latterly studying the T cell re-
sponse against HIV has been a major focus, and his group
has designed and tested two candidate HIV vaccines in
phase I clinical trials. Based through most of his research
career in Oxford, he was knighted in 2008 for services
to medical sciences, and has just completed 12 years as
Director of the Weatherall Institute of Molecular Medicine.
In this 30th year since the discovery of HIV as the
cause of AIDS, we asked Sir Andrew to give us his per-
sonal perspective on the progress towards a vaccine.
Would you like to start by telling us how and
when you first started working on HIV?
We started in 1986 or 1987 when my laboratory was fo-
cused on studying immune responses to influenza. I actu-
ally had a clinical training fellow - Douglas Nixon - who
was studying to be a clinical virologist. He wanted to come
and do a PhD and we discussed the possibility of looking
at another virus and thought HIV would be worth having
a look at. We did some preliminary experiments and
found that we could look at T cell immune responses, so
we started to work on that. This is all around the time that
Alain Townsend’s work on the peptides was getting to a
very exciting stage.
Is this when you and Alain Townsend were
discovering how peptides derived from viral
proteins were delivered to the surface of infected
cells and presented to T cells?
Yes, so we were quite busy. We started working on HIV
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reproduction in any medium, provided the orworking on immune responses to HIV. A lot of virolo-
gists were already working on it of course. So we
thought we’d start on it in quite a small way, but realiz-
ing that if the experiments worked, it would probably
take over our lives. Which it more or less has done.
Was the hope always to find anti-HIV responses
that can protect against infection, and develop a
vaccine capable of eliciting these? Why do you
think it’s been so difficult?
Well, the vaccine is problematical. But it’s not alone in
that. Vaccines for malaria and TB and hepatitis C virus are
all difficult problems. So not every vaccine is easy. I think
that the reason that HIV is so difficult is that there’s really
no example of humans who have become infected, have
cleared the virus and are protected from re-infection. So
you don’t have that precedent to work with which you
have in almost every other virus infection. Then the virus
of course is incredibly variable and in fact the more that
we know about it, the more variable it appears. That
makes it very easy for it to evade immune responses. Also
it persists and it can hide as a latent pro-virus. So oncetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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So for a vaccine to work, you’ve got a very narrow
window, probably really just preventing the initial infec-
tion. And that’s proving very hard to do with vaccines that
primarily elicit antibodies.If you think about vaccines that have been
successful, have they all been vaccines that
induce protective, neutralizing antibodies?
Yes probably, nearly all of them. One possible exception
is the BCG vaccine against TB. But BCG is only very
partially effective really. All of the really successful - 90%
efficient or more - vaccines are vaccines that induce
neutralizing antibodies.Can you explain, just briefly, why HIV doesn’t
seem to be very good at inducing neutralizing
antibodies?
It was thought that it was very bad at inducing neutraliz-
ing antibodies, although recently there are lots of studies
looking at patients who are chronically infected, who do
actually make pretty good neutralizing - broadly neutral-
izing - antibodies, but it’s too late for them. They can
take 3 to 5 years before they come up. One of the prob-
lems is that the first antibodies that are made are not
neutralizing. Within two weeks of infection people will
make some antibodies to parts of the virus - the enve-
lope protein - but they are non-neutralizing. And then
there’s a rather long period before they make antibodies
that will neutralize the autologous or infecting virus -
that’s about 80 days. Then it may be years before they
make antibodies that broadly neutralize many different
viruses. The reasons, I think, are partly that there are
many sites where the antibody seems to bind to but
doesn’t effectively neutralize. There are many sites where
the virus just varies - where it has variable loops - so
that the antibodies might neutralize that virus, but it can
very easily escape by mutation. And then there are rela-
tively few sites that are highly conserved, which the virus
can’t really change without big fitness costs, such as the
CD4 binding site which it uses to infect cells [1]. It
seems to be very hard to get antibodies to those sites.
They do come up in some patients after 3 to 5 years, but
these antibodies are very mutated from their germline
ancestor antibodies. There’s been a lot of selection over
several years. So sometimes they accumulate 50 som-
atic mutations before they acquire the specificity and
affinity of a broadly neutralizing antibody. But even
then they are a minority population in all the anti-
bodies - they’re mainly present at under 1% of all the
antibodies being made. The challenge is to design a
vaccine that will somehow induce lots of these protect-
ive antibodies [2]What about T cell immunity - is there evidence of
that being effective in controlling the infection?
There’s good evidence that cytotoxic CD8 T cells will con-
trol or partially control the infection once it’s started and
that indeed good T cell responses will control better than
poor T cell responses. They may have to be good in a
number of senses - to be good killers, to make good cyto-
kines and chemokines, to target, again, the more con-
served regions of the virus so that the virus can’t escape
very easily and to be present in adequate numbers to con-
trol the response. Because CD8 T cells detect intracellular
infections when the viral peptides are presented at the
cell surfaces by host HLA molecules, which are highly
polymorphic, you get particular HLA types being favor-
able, such as HLAB57, which, probably by chance, picks
out conserved regions of the Gag protein. It may also be
that T cell responses targeted to Gag are more effective
than T cell responses to Envelope - there’s good evi-
dence for that. Not clear why, although Gag is more
conserved. So a number of factors give variable T cell
responses and some people control better than others.
But the T cell responses are important in getting some
degree of control of infection [3].And is this the basis on which you’ve been
working towards designing a T cell vaccine?
Well, we’ve been arguing that there’s a good case for a T
cell vaccine as a backup to an antibody-inducing vaccine
or as a possible alternative, at least in those who were
not protected by the antibody vaccine. If you couldn’t
get 100% efficacy, then having a strong T cell response
may be useful as it would lead to better control of the
virus. Indeed, there are many infections we have, such as
Epstein-Barr virus and cytomegalovirus, where the T
cells permanently control the infection within people,
and they remain healthy. So you could envisage a situ-
ation where we have strong T cell responses to HIV and
HIV controlled long term and at very low levels, where
it’s not causing any trouble. Rather like being on per-
manent anti-retroviral therapy. There’s also a study in
macaques from Louis Picker in the last two or three
years which shows that if he can establish very strong
early T cell responses, that he could, in some cases,
eradicate the infection in the monkeys via T cells [4].So in that case, a T cell vaccine really worked?
Yes, the macaques were given a rather special vaccine
which was vectored by cytomegalovirus, which is a per-
sistent infection, which I’ve just said is usually not ter-
ribly harmful on its own but maintains a very strong
CD8 T cell response to cytomegalovirus, in this case
with inserted HIV antigen. This seems to be particularly
effective at stimulating and maintaining effective T cell
McMichael BMC Biology 2013, 11:60 Page 3 of 5
http://www.biomedcentral.com/1741-7007/11/60responses, and in some cases eradicating the virus when
it is subsequently given as a challenge.
Is this a vaccine vector that could be used in
humans?
There’s an argument about that because it would be a
persisting infection. So once given, it would be difficult
to get rid of it if it was found to have side effects 20
years later. Although it’s thought to be a fairly harmless
virus, there are situations where it can cause disease,
particularly in immunodeficiency. A disease caused by
the vaccine would not be a very good situation. So there
are some concerns that it might not be quite as safe as
people who are advocating it sometimes suggest. I think
the regulators would have concerns. The alternative is to
try and find something else that would be safer, that
would stimulate the same kind of T cell response.
Could you briefly explain the design of the
particular vaccines that you are developing?
We’re trying to get the immune response to focus on
conserved viral peptides that can be presented to T cells.
So we’re making an artificial construct, which incorpo-
rates fragments of the HIV genome that are fairly well
conserved across the major clades. In our initial analysis,
we chose regions that were less than 6% variable in
amino acid sequence across the four major clades. Then
we stitched those 14 fragments together so it’s about a
quarter of the total of HIV. They are then used as an im-
munogen. Working with Tom Hanke, who designed it
with me [5], and Lucy Dorrell, who does all the clinical
studies, we’ve done some phase 1 trials with it [6]. We’re
getting quite encouraging results. At least we can get quite
strong immune responses to this candidate vaccine.
Is there quite a lot of variability in how strong the
responses are across the population, given that
everybody has different antigen presenting HLA
molecules? Is that a difficulty?
In phase 1 trials we’ve tested it in about 30 people so far -
they all respond to it, to varying degrees and varying
breadths. Some will respond to multiple peptides, others
probably to fewer peptides. As we dissect that, that may
turn out to be important. We may have to figure out ways
to try and ensure that everybody, whatever their HLA
type, has a certain level of breadth in their response.
If you look at the people who do control HIV well,
do they have a good breadth of response to
different conserved viral peptides?
We’ve just published a paper describing this [7], al-
though it was a mix of people, some with good HLA
types and some without. We were looking at the rate at
which the virus escaped from the T cell responses inacute infection. The more conserved across the viruses
that the peptide epitope seen by T cells is, the slower the
virus would escape from this T cell response by a muta-
tion. The other factor that was important was that if the
response to that peptide was strongly immunodominant,
the virus would escape more rapidly. If you put together
an immunodominant response and a slow escaping con-
served epitope, then you must get the strongest pressure
on the virus. People with protective HLA types do
exactly that. They make strongly immunodominant re-
sponses to conserved epitopes. So we think that what we
need to do with a vaccine is to get these strong re-
sponses to conserved epitopes, maybe sometimes epi-
topes that in people with less favorable HLA types
would not normally respond to. But if a vaccine could
stimulate those strong dominant responses, they may get
much better protection.
Presumably if the virus does manage to escape an
immunodominant response to a conserved
epitope, it will be at some fitness cost?
Well that’s the hope. There is some evidence that that is
the case for some of these well studied epitopes. But the
idea would be to make that a sort of general situation so
that if the virus did escape, it will be less fit. And then
you maintain some advantage over the virus.
Are you getting to the point where you’d be able
to progress from phase 1 trials onto phase 2?
Well, we’d like to. What we’re doing at the minute is
we’re dissecting these immune responses in as much de-
tail as we can. We’re particularly interested to see how
well these T cells suppress virus-infected cells, not just
looking at the T cell effector functions, like killing or
cytokine production, but actually looking at their ability
to suppress autologous CD4 cells infected with a variety
of viruses to see whether we get something that’s equiva-
lent to the holy grail for the neutralizing antibodies -
neutralizing a whole variety of different viruses in vitro.
We can do the same kind of thing with the T cells, sup-
pressing their replication in vitro. Then we think we
could sort of predict whether this vaccine might work or
have an effect in vivo. The more we can do in vitro, the
cheaper and easier and faster it is. And we can gradually
build a case to try and test this in an efficacy trial
in vivo.
Are there any animal models you can use?
Well, it’s a little tricky. You could do some parallel ex-
periments in monkeys for SIV, but it wouldn’t actually
be the same vaccine because of the variation within SIV
and HIV is not identical. We’d have to redesign a whole
new construct, so it wouldn’t be an exact parallel. But
we have discussed that and we are thinking about it.
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of this type?
The problem is, I think, they don’t make terribly strong
T cell responses. They do make some, but they’re quite
difficult to work with I think. And obviously expensive
and labor intensive. But they could be useful and that’s
something we probably need to look at again. My feeling
would be, if we could get this vaccine stimulating really
strong virus inhibition across a range of viruses by CD8
T cells in vitro, then we could make quite a strong case
for it to be tested in vivo for efficacy. But I think we
wouldn’t be in a position to argue that for a year or two
yet. Then to go into an efficacy trial, it’s a huge hurdle of
getting someone to fund it because they cost millions
and they take years and they take huge teams. I think it
would have to be tested alongside a parallel construct that
would generate and accumulate neutralizing antibodies.
And then how would you know which was the
most effective?
I think that if you got no infections, that would be the
antibody. That would be the wonderful result, that you
had complete protection. On the other hand, if you did
get some infection, then you’d look at the degree of con-
trol of those infections, relative to the placebo group.
And you would be looking to see whether you got lower
virus loads and slower progression. You could probably
tell which was doing which.
If you look at the recent Thai vaccine trials that
reported a modest efficacy, did they see any
reduction in viral load?
No, they didn’t really have any CD8 T cells to speak of
[8]. But it would be that sort of result. If you got a result
where maybe you got 50% efficacy in terms of full pro-
tection, which would be very good, and then in the other
50% that got infected, you’d be looking to see whether
the CD8 T cells had given you lower viral loads. You
could then talk about how long could they be safe going
before they’d have to go on medication. Ideally, you’d
want that number to be decades.
Well that would be a tremendous advance
It would. I don’t think it’s out of reach. It’s difficult. And
it may be someone else’s vaccine will do it better than
ours. But I think that is an achievable aim.
Is your vaccine designed to target the mucosal
part of the immune system?
Well, I’m a bit more lukewarm about that. With the sort
of T cell vaccine we’re thinking of, we’re probably com-
ing in to act after the initial mucosal infection has
spread into lymphoid tissues. You could say that the ma-
caque vaccine from Louis Picker is similar, in that it’s aT cell vaccine, and it doesn’t eradicate the infection
within the first 5 or 7 days when it’s in the genital mu-
cosa or rectal mucosa. It’s curing the infection perhaps
weeks, or months, later when it’s already spread around
the body.
So that result is possibly the most encouraging
one yet?
Well it’s very exciting. But there’s also lots of things puz-
zling about it. It doesn’t happen in all macaques. So why
doesn’t it happen in some of them? What are they doing
differently? I’m not clear if we know what the answer to
that is. But again, it’s something that should be solvable.
Would you say that your vaccines are generating
T cell immunity in a way that is different from
other vaccines such as the STEP vaccine?
The STEP vaccine trial in 2009 tested whether a vaccine
(adenovirus-5 vectored HIV Gag Pol and Nef) could en-
able better control of virus in those infected, but it did
not [9]. I think our vaccine is doing something a bit dif-
ferent by focusing T cell responses only on the con-
served regions of the virus so that vaccine-virus matches
are better and escape is less likely. I know there are
some other similar approaches, at various stages of de-
velopment, that may be doing similar things now that
are not published. We’re trying to do something differ-
ent and it looks like we’re sort of part of the way there.
Although I think we still need to do a bit more to be
sure it’s going to work. Or has a chance of working.
It sounds like you’re an optimist
Well you have to be an optimist to work in this field.
I’d like to add, just briefly, that there’s a lot of interest
in trying to eradicate the virus in patients with mixtures
of drugs and activators of latent virus. Adding in an im-
mune response, as well, might help that process. So
these sorts of combined approaches could be used
in therapeutic strategies. One of my colleagues, Lucy
Dorrell, is working on that.
That sounds promising. Has this approach been
tried with other viral vaccines to persistent viruses,
such as the vaccine against human papillomavirus?
Has that been tested in people who already have
the virus?
Yes there’s quite a bit of work going on there. I’m not
sure it can eradicate the infection - that’s the trouble.
But again, that’s a vaccine aimed at stimulating anti-
bodies. You may need more cellular immune responses
to eradicate. I think it’s an interesting idea that one
might, for some of these persisting viruses, not just HIV,
but hepatitis C, for example, be able to use combinations
of drugs and immune responses in an aggressive sort of
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people. There’s certainly a lot of interest in that.
Will it actually be a lot easier to get a trial going
to test that idea, in the case of HIV and your
vaccines, than to do the trials to establish
whether there’s protection?
It would be easier than HIV vaccine efficacy trials,
which really do cost millions and millions. An eradica-
tion type of study, one could do on a small group of pa-
tients. Because at the moment if you can do it in one
patient, you’d cause a sensation. If you can do it in one,
you can probably do it in more.
Note
This article is part of the cross journal collection HIV
thirty years on. Other articles in this series can be found
at [10].
Published: 21 May 2013
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